The study behind the trial that Novo Nordisk stopped early last year for efficacy reasons has been published in the NEJM. And sure enough, it’s reporting that semaglutide (aka Wegovy, Ozempic) is helpful, even life-saving, for patients with type 2 diabetes and chronic kidney disease.

To date, chronic kidney disease has no cure, whilst affecting more than 1 in 7 Americans.

From Nature’s reporting:

…those who received semaglutide injections weekly were 24% less likely to have ‘major kidney disease events’, including kidney failure and dying owing to kidney complications

…

Participants who received semaglutide were also 29% less likely to die from heart attacks and other major cardiovascular incidents than were those who got a placebo, and 20% less likely to die from any cause during the trial period.

Of course it’s not the first time that this drug has been shown to save lives.